Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study
- PMID: 12488303
- DOI: 10.1093/annonc/mdg009
Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study
Abstract
Background: Docetaxel (Taxotere) is a potent anticancer agent, with proven efficacy as first-line therapy in non-small-cell lung cancer (NSCLC). The aim of this large randomised multicentre phase III study was to evaluate docetaxel in the neoadjuvant (pre-operative) setting.
Patients and methods: Patients with stage IIIA or locally treatable IIIB NSCLC were randomly assigned to receive neoadjuvant docetaxel (n = 134) or no chemotherapy (n = 140) before surgery/curative-intention radiotherapy. Patients received up to three 3-weekly cycles of docetaxel (100 mg/m(2)) as 1-h intravenous infusions.
Results: Median survival was 14.8 months in the docetaxel group and 12.6 months in the control group. Median times to disease progression were 9.0 months (docetaxel arm) and 7.6 months (control arm). There were three complete responses and 25 partial responses in patients treated with docetaxel who were evaluable for response (n = 101). Docetaxel was well-tolerated: 103 patients (77%) received all three planned cycles. The major toxicity was grade 4 neutropenia (69 patients, 55%) and neutropenic fever (eight patients, 6%). Radiotherapy was well-tolerated after docetaxel administration.
Conclusions: Neoadjuvant docetaxel is generally well-tolerated and shows a promising trend towards longer survival in patients with NSCLC.
Similar articles
-
Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.Ann Oncol. 1999;10 Suppl 5:S69-72. doi: 10.1093/annonc/10.suppl_5.s69. Ann Oncol. 1999. PMID: 10582143 Clinical Trial.
-
The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.Semin Oncol. 1997 Aug;24(4 Suppl 14):S14-30-S14-32. Semin Oncol. 1997. PMID: 9335522 Clinical Trial.
-
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.Lung Cancer. 2003 Apr;40(1):79-84. doi: 10.1016/s0169-5002(02)00532-9. Lung Cancer. 2003. PMID: 12660011
-
Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer.Semin Oncol. 2001 Feb;28(1 Suppl 2):22-7. Semin Oncol. 2001. PMID: 11284621 Review.
-
Docetaxel for previously treated non-small-cell lung cancer.Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):45-51. Oncology (Williston Park). 2002. PMID: 12108897 Review.
Cited by
-
A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).Br J Cancer. 2008 Sep 16;99(6):852-7. doi: 10.1038/sj.bjc.6604613. Br J Cancer. 2008. PMID: 18728643 Free PMC article. Clinical Trial.
-
Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer.World J Surg Oncol. 2010 Feb 5;8:8. doi: 10.1186/1477-7819-8-8. World J Surg Oncol. 2010. PMID: 20137082 Free PMC article.
-
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08. Transl Lung Cancer Res. 2015. PMID: 25806348 Free PMC article. Review.
-
The role of induction therapy for resectable non-small cell lung cancer.Drugs. 2007;67(3):321-32. doi: 10.2165/00003495-200767030-00001. Drugs. 2007. PMID: 17335293 Review.
-
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.Lancet. 2014 May 3;383(9928):1561-71. doi: 10.1016/S0140-6736(13)62159-5. Epub 2014 Feb 25. Lancet. 2014. PMID: 24576776 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical